论文部分内容阅读
目的:研究罗格列酮联合胰岛素治疗2型糖尿病的血糖、血脂改善效果及安全性。方法:315例2型糖尿病患者按入院先后顺序分为观察组(157例)和对照组(158例)。对照组予门冬胰岛素30注射液,观察组在对照组基础上加用罗格列酮片。两组患者疗程均为3个月。观察两组患者治疗前后糖化血红蛋白(Hb A1c)、血糖(FBG、2h PG)、血脂(TG、TC、HDL-C、LDL-C)等指标变化,以及药品不良反应发生情况,比较两组胰岛素用量和血糖达标时间。结果:治疗后,两组FBG、2h PG和Hb A1c均较治疗前降低(P<0.05),且观察组患者各项指标均低于对照组(P<0.05)。治疗后,两组患者TG、TC、LDL-C均较治疗前下降(P<0.05),而HDL-C无明显变化(P>0.05)。观察组治疗后TG、TC水平显著低于对照组(P<0.05),而两组治疗后LDL-C、HDL-C水平比较,差异无统计学意义(P>0.05)。治疗后,观察组胰岛素用量显著低于对照组,血糖达标时间也明显短于对照组(P<0.05)。两组低血糖事件和药品不良反应发生例数比较,差异无统计学意义(P>0.05)。结论:罗格列酮联合胰岛素治疗2型糖尿病,可显著改善患者的血糖、血脂指标,减少胰岛素用量,缩短血糖达标时间,且安全性较高,值得广泛推广使用。
Objective: To study the effect and safety of rosiglitazone combined with insulin in the treatment of type 2 diabetes on blood glucose and blood lipid. Methods: 315 patients with type 2 diabetes were divided into observation group (157 cases) and control group (158 cases) according to the sequence of hospital admission. Control group aspart insulin 30 injection, the observation group in the control group based on the addition of rosiglitazone tablets. Two groups of patients were treated for 3 months. The changes of Hb A1c, FBG, HDL-C, LDL-C and other adverse reactions were observed before and after treatment. The incidence of adverse drug reactions was compared between the two groups. The levels of insulin, Dosage and blood glucose compliance time. Results: After treatment, FBG, 2h PG and Hb A1c in both groups were lower than those before treatment (P <0.05), and all indexes in the observation group were lower than those in the control group (P <0.05). After treatment, TG, TC and LDL-C in both groups were significantly lower than those before treatment (P <0.05), while no significant changes were found in HDL-C (P> 0.05). The levels of TG and TC in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in the levels of LDL-C and HDL-C between the two groups after treatment (P> 0.05). After treatment, the amount of insulin in the observation group was significantly lower than that of the control group, and the time of reaching the blood glucose level was also significantly shorter than that of the control group (P <0.05). There was no significant difference between the two groups in the number of hypoglycemic events and adverse drug reactions (P> 0.05). Conclusion: Rosiglitazone combined with insulin in the treatment of type 2 diabetes mellitus can significantly improve the patients’ blood glucose and blood lipid, reduce the dosage of insulin, shorten the time of reaching the blood sugar standard, and it is safe and worthy of wide application.